“Comparative Analysis of the Use of Technetium-99m Labeled Recombinant Target Molecules at Doses of 1000 and 2000 μg for Radionuclide Diagnostics of HER2-Positive Breast Cancer”. Voprosy Onkologii, vol. 68, no. 1, Feb. 2022, pp. 60-65, https://doi.org/10.37469/0507-3758-2022-68-1-60-65.